Introducing TrumpRx.gov, the White House’s Direct-to-Consumer Platform for Prescription Drugs

Pfizer has become the first pharmaceutical company to participate in President Donald Trump’s Most Favored Nation pricing, which requires the company to offer medications at a discount and invest in production in the United States.

Pfizer’s products will be offered on a website that hasn’t yet launched, called TrumpRx.gov. The program, at least initially, seems to be geared toward patients who access care through Medicaid. But officials said during a press conference they see a future where these prices will also apply in the Medicare program and commercial plans.

In July, Trump had sent letters to the heads of pharmaceutical companies outlining steps for lowering drug costs by matching them to prices in other developed nations. To determine those prices, the administration started with net prices after fees and rebates. These were indexed to a basket of countries, and that became the starting point for negotiations.

The large majority of Pfizer's primary care treatments and some select specialty brands will be offered at savings that will range as high as 85% and on average 50%.

Trump said during the press conference that this deal will allow consumers to access significant discounts off list prices. The White House was cited as an example. Xeljanz (tofacitinib), an oral medication for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, will be available at a 40% discount to patients who purchase directly, and Zavzpret (zavegepant), which is used to treat migraines, will be sold directly to patients at a 50% discount.

With this agreement Pfizer agreed to begin producing drugs in the United States, but the company has three years to make that a reality. The company plans to invest $70 billion in manufacturing and research in the United States over the next few years.

In a separate press release, Pfizer executives said this investment builds upon the company's more than $83 billion investment in American biotech innovation from 2018 to 2024. Pfizer plans to focus on the development of next-generation therapies, especially in cancer, obesity, vaccines, and inflammation and immunology.

Albert Bourla

Pfizer chairman and CEO Albert Bourla said during the press conference the agreement ensures that the company’s products are not subject to tariffs. Tariffs, he said, create an uncertainty for the industry, substantially reduce the company’s valuations, and create concerns for the company’s ability to invest.

“Because of this uncertainty, it was what was holding people from investing in the pharmaceutical industry, which resulted in a significant reduction of our multiples. Our multiples are at historical lows. Well, now we have clarity about what the framework for the U.S. price is, and we will abide by that. Going forward, this is how things will be priced in the U.S. and the world,” he said during the press conference.

Marty Makary, M.D., commissioner of the FDA, said at the press conference that the agency will work with pharmaceutical companies who make the investment in U.S. development by having inspectors available during construction so companies don’t have to wait until completion for an inspection.

Many of the details about the agreement with Pfizer have not been released, but in a statement, the National Association of Chain Drug Stores (NACDS) President and CEO Steven C. Anderson expressed concern about the impact on pharmacies. "The health and wellness of Americans relies on their pharmacists and pharmacies—the most accessible and among the most trusted healthcare destinations. Americans’ access to their pharmacies, the face of neighborhood healthcare, must not be a casualty in the effort to address the harms that PBMs have inflicted," he said.